Brain and Central Nervous System Tumors Clinical Trial
Official title:
Phase I Study of Enzastaurin and Temozolomide in Patients With Gliomas
RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy,
such as temozolomide, work in different ways to stop the growth of tumor cells, either by
killing the cells or by stopping them from dividing. Giving enzastaurin together with
temozolomide may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of enzastaurin when
given together with temozolomide in treating patients with primary gliomas.
Status | Active, not recruiting |
Enrollment | 28 |
Est. completion date | |
Est. primary completion date | November 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically confirmed primary supratentorial glioma - WHO histologic grade 3 or 4 - Patients who have undergone prior treatment for low-grade glioma that has transformed to glioblastoma (biopsy proven) allowed - Amenable to standard temozolomide treatment - First or second recurrent disease after prior surgery and/or radiotherapy OR newly diagnosed disease that is not amenable to radiotherapy (e.g., multifocal disease) PATIENT CHARACTERISTICS: - ECOG or WHO performance status 0-2 - Hemoglobin = 10.0 g/dL - Neutrophil count = 1,500/mm^3 - Platelet count = 100,000/mm^3 - Bilirubin = 1.5 x upper limit of normal (ULN) - Alkaline phosphatase and transaminases = 2.5 x ULN - Serum creatinine < 1.7 mg/dL - Not pregnant or lactating - Negative pregnancy test - Fertile patients must use effective contraception - Clinically normal cardiac function - No ischemic heart disease within the past 6 months - No clinically significant abnormalities or uncontrolled cardiac arrhythmia by ECG - QTc interval = 450 msec (males) or = 470 msec (females) by baseline 12-lead ECG - No history of congenital long QTc syndrome - No history of stroke - No other prior or concurrent malignancy within the past 5 years except cone biopsied carcinoma of the cervix or adequately treated basal or squamous cell skin carcinoma - No unstable systemic diseases - No active uncontrolled infections - No uncontrolled hypertension - No psychological, familial, sociological, or geographical condition that would preclude study participation - Must be able to swallow tablets PRIOR CONCURRENT THERAPY: - See Disease Characteristics - No more than 1 prior chemotherapy regimen in the adjuvant setting or for first recurrence - Prior temozolomide allowed provided there was no disease progression during temozolomide treatment or within 6 weeks of completing temozolomide treatment - Prior surgery for primary brain tumor within the past 3 months allowed - Patients who are receiving corticosteroid treatment must be on a stable or decreasing dose for at least 1 week before study entry - At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) - At least 14 days since prior and no concurrent enzyme-inducing antiepileptic drugs including, but not limited to, any of the following: - Phenytoin - Carbamazepine - Phenobarbital - More than 30 days since prior and no other concurrent investigational treatments - No concurrent anticoagulant treatment (e.g., warfarin) - Low molecular weight heparin for patients who require anticoagulant therapy after starting study treatment may be allowed - No concurrent routine use of colony-stimulating factors - No other concurrent anticancer agents |
Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United Kingdom | Beatson West of Scotland Cancer Centre | Glasgow | Scotland |
Lead Sponsor | Collaborator |
---|---|
European Organisation for Research and Treatment of Cancer - EORTC |
United Kingdom,
Rampling R, Sanson M, Gorlia T, Lacombe D, Lai C, Gharib M, Taal W, Stoffregen C, Decker R, van den Bent MJ. A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054). Neuro Oncol. 2012 Mar;14(3):344-50. doi: — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recommended phase II dose | Yes | ||
Primary | Dose-limiting toxicity | Yes | ||
Secondary | Response rate | No | ||
Secondary | Progression-free survival | No | ||
Secondary | Overall survival | No | ||
Secondary | Pharmacokinetics of enzastaurin hydrochloride alone and in combination with temozolomide | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00006080 -
Fenretinide in Treating Patients With Recurrent Malignant Glioma
|
Phase 2 | |
Recruiting |
NCT00887146 -
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
|
Phase 3 | |
Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
Completed |
NCT00621686 -
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT00227032 -
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT00243022 -
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
|
Phase 2 | |
Active, not recruiting |
NCT00087815 -
Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain
|
N/A | |
Active, not recruiting |
NCT00278278 -
Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
|
Phase 3 | |
Completed |
NCT00416819 -
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
|
N/A | |
Completed |
NCT00052286 -
Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer
|
N/A | |
Completed |
NCT00006093 -
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
|
Phase 1/Phase 2 | |
Recruiting |
NCT00004129 -
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00004212 -
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT00003417 -
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
Completed |
NCT00003173 -
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
|
Phase 2 | |
Completed |
NCT00003020 -
LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases
|
Phase 1 | |
Completed |
NCT00008008 -
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
|
Phase 2 | |
Completed |
NCT00003484 -
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
|
Phase 1 |